Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14




Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

DURHAM, N.C.–(BUSINESS WIRE)–Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, including the Company’s late-stage clinical programs in vascular trauma repair and AV access for hemodialysis.

A live audio webcast of Dr. Niklason’s presentation will be available at https://icrinc.touchcast.com/showtime/icr-conference/embed/cc5377f9-2ef3-e9b8-be58-1469409cc875, and an archived version will be available after the conference.

In addition to keynote speakers Peyton and Eli Manning, the 23rd annual conference includes speakers from more than 250 public and private companies in the apparel, automotive, cannabis, consumer, financial, foodservice, healthcare, real estate, and technology industries. The four-day invitation-only event aims to gain insight into future trends and growth strategies, and to exchange ideas through meaningful networking. To learn more, visit www.icrconference.com.

About Humacyte

Humacyte, Inc., a privately held regenerative medicine company based in Durham, North Carolina, is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues to improve the lives of patients and transform the practice of medicine. Humacyte believes the technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. Leveraging our novel, best-in-class, scalable technology platform, Humacyte is developing proprietary, bioengineered, acellular human tissues that are designed to regenerate and have been demonstrated to become the patient’s own living tissue. The company’s goal is to develop and manufacture these tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. These efforts, if approved, would benefit people with traumatic injuries, End-Stage Renal Disease (ESRD), and peripheral arterial disease (PAD), and could potentially help patients needing vascular reconstruction and Coronary Artery Bypass Grafting (CABG). Humacyte was co-founded in 2004 by Laura Niklason, M.D., Ph.D., a world leader in cellular therapies/regenerative medicine and adjunct professor at Yale University; biomedical engineer Dr. Shannon Dahl; and molecular biologist Dr. Juliana Blum. Visit humacyte.com for more information.

Contacts

Investor Relations Contact
Mike Piccinino, CFA (Westwicke, IR for Humacyte): mike.piccinino@westwicke.com
Media Relations Contact
Nirav Suchak (ICR, PR for Humacyte): 646-277-1257; nirav.suchak@icrinc.com